摘要
目的观察吉西他滨联合顺铂化疗方案(CP)对非小细胞肺癌(NSCLC)患者外周血前梯度蛋白2(AGR2)表达的影响,并探讨其临床意义。方法选取40例NSCLC患者给予吉西他滨联合顺铂化疗方案作为治疗组,并以20例健康人群为正常对照组,采用ELISA法分别检测治疗组化疗前后及正常对照组AGR2的表达,分析AGR2表达水平与临床病理特征的关系。结果 (1)GP化疗总有效率为45.0%;(2)治疗组化疗前AGR2水平(14.36±3.50ng/ml)明显高于正常对照组(2.32±1.12ng/ml)(t=8.005,P=0.000);化疗后血清AGR2水平(7.35±1.54ng/ml)比化疗前明显降低(t=4.471,P=0.001);(3)化疗有效的患者血清AGR2水平(7.28±1.31ng/ml)较化疗前(14.45±3.20ng/ml)明显下降,差异有统计学意义(t=5.078,P=0.000)。而化疗无效的患者血清AGR2水平(12.45±3.04ng/ml)较化疗前(13.95±2.78ng/ml)略有下降,但差异无统计学意义(t=0.891,P=0.394);(4)AGR2表达水平与肺癌临床分期、组织类型密切相关(均P=0.000);化疗后鳞癌患者AGR2水平比腺癌下降稍明显。结论吉西他滨联合顺铂化疗可有效降低肺癌患者血清AGR2的表达,NSCLC患者化疗前后AGR2的变化与肺癌的进展及转移密切相关。
Objective To investigate the change and clinical significance of serum AGR2 in NSCLC patients treated with Gemcitabine and Cisplatin regimen. Methods The level of serum AGR2 was detected by ELISA in 40 patients with NSCLC （treatment group） ,20 healthy volunteers （control group）. The relationship of serum AGR2 wtih clinical pathologic features was analyzed. Results （ 1 ） Total effective rate was 45.0% in the GP chemotherapy; （ 2 ） The expression of serum AGR2 in treatment group （ 14.36 ＋ 3.50ng/ml） was siginficanfly higher than that in control group （ 2.32 ＋ 1.12ng/ml ） （ t = 8.005, P = 0.000 ） ; Compared to before chemotherapy （ 14.45 ＋ 3.20ng/ml ）, serum level of AGR2 after chemotherapy （ 7.35 ＋ I. 54ng/IIfl） was significantly lower in NSCLC patients （t = 4.471,P = 0. 001 ） ;（ 3 ）In the effective chemotherapy patients, ser- um level of AGR2 after chemotherapy（7.28 ＋ 1.31ng/ml） was obviously lower than before chemotherapy （ 14.45 ＋ 3.20ng/ ml） （t = 5. 078, P = 5. 078 ）. And compared with before chemotherapy （ 13.95 ＋ 2.78ng/ml）, serum AGR2 level after chemo- therapy （ 12.45 ＋ 3.04ng/ml） declined slightly in the invalid chemotherapy patients （t = 0.891, P = 0. 891 ）. （4） The level of serum AGR2 in NSCLC patients was closely correlated to clinical stages and histologic type （ all P = 0. 000） ; Compared with adenocarcinoma, AGR2 reduction is slightly obvious in patients with squamous cancer after chemotherapy. Conclusion Gemeitabine and Cisplatin regimen can effectivly reduce the level of serum AGR2. In NSCLC patients, the change of serum AGR2 before and after chemotherapy is closely related to the progression and metastasis of lung cancer.
出处
《临床合理用药杂志》
2016年第23期3-4,10,共3页
Chinese Journal of Clinical Rational Drug Use
